Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE)

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Dana-Farber Cancer Institute
Study ID
NCT06469307
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • DIVERSE Review Process — OTHER
    A participant and community-based review system for clinical research protocols that elicits and collects feedback on investigator-initiated protocol reviews.

Study Details

The purpose of this research study is to enhance inclusion and diversity in clinical trial enrollment by training participants to perform and provide feedback through a community-based protocol review process, called DIVERSE.

Key Dates

Start date
Dec 9, 2024
Status verified
May 2025
Primary completion
Jul 1, 2026
Completion
Jun 30, 2027

Study Design

Enrollment
40 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
HEALTH_SERVICES_RESEARCH

Arms

  • Other: DIVERSE Community Advisory Board (CAB)
    Enrolled participants will complete: * Confidentiality agreement and demographic questionnaire * Online training and in-person or remote training with study team * Timely DIVERSE review of protocols * Audio recorded meeting (in-person, remote, or via phone call) with study team to present review findings * Semi-structured exit interview and/or focus group with study staff to provide feedback
  • Other: DIVERSE Investigators
    Enrolled investigator participants will complete: * Brief Feedback Survey * Request DIVERSE reviews and complete request form * Acceptability of Intervention Measure questionnaire * Semi-structured exit interview and/or focus group with study staff to provide feedback

Primary Outcome Measure

Protocol Review Completion Rate [ Time Frame: 18 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Dana-Farber Cancer InstituteBostonMassachusetts02215
Andrew Hantel, MD
[email protected]
617-582-9394
Andrew Hantel, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Boston, MA

By condition
Leukemia (other)
By specialty
OncologyBlood cancer
By research site
Dana-Farber Cancer Institute· Boston, MA

Related Studies